Frankfurt
16.04.26 | 08:04
0,139 Euro
-1,28 % -0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.04. | IRLAB Therapeutics: IRLAB to Present at Redeye Healthcare Day 2026 | 239 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 9, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 17.03. | IRLAB Therapeutics: IRLAB to Present Clinical and Preclinical Data at The AD/PD 2026 - 20th International Conference on Alzheimer's & Parkinson's Diseases | 315 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / March 17, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 02.03. | IRLAB Therapeutics: IRLAB Participates in Life Science Day in Gothenburg on March 4, 2026 | 247 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / March 2, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the... ► Artikel lesen | |
| IRLAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.02. | IRLAB Therapeutics: IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease | 317 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA)... ► Artikel lesen | |
| 25.02. | IRLAB Therapeutics: IRLAB Publishes Full-Year Report for The Period January - December 2025 | 397 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 25, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 20.02. | IRLAB Therapeutics: IRLAB has Received Scientific Advisory Board Confirmation on Next Steps for Pirepemat | 310 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 20, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 18.02. | IRLAB Therapeutics: IRLAB: Invitation to the Year-End Report 2025 Presentation and Webcast | 246 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 18, 2026 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's... ► Artikel lesen | |
| 19.01. | IRLAB Therapeutics: IRLAB Enters Collaboration Agreement with Danish Biotech Company Biomia ApS Applying the Integrative Screening Process | 323 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / January 19, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA),... ► Artikel lesen | |
| 23.12.25 | IRLAB Therapeutics: IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson's Disease | 368 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / December 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB... ► Artikel lesen | |
| 11.12.25 | IRLAB Therapeutics: The European Patent Office Intends to Grant a New Patent for IRLAB's Mesdopetam | 345 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / December 11, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's... ► Artikel lesen | |
| 27.11.25 | IRLAB Therapeutics: IRLAB Participates in Redeye Technology & Life Science Day on December 3, 2025 | 343 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / November 27, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 20.11.25 | IRLAB Therapeutics: Nomination Committee Appointed for IRLAB's Annual General Meeting 2026 | 355 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / November 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that... ► Artikel lesen | |
| 07.11.25 | IRLAB Therapeutics: IRLAB Receives Acceptance for Two Abstracts at AD/PD 2026: The 20th International Conference on Alzheimer's and Parkinson's Diseases | 392 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / November 7, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 29.10.25 | IRLAB Therapeutics: IRLAB Publishes Interim Report for The Period January - September 2025 | 467 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 29, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 23.10.25 | IRLAB Therapeutics: IRLAB: Invitation To The Interim Report For Q3 2025 Presentation And Webcast | 348 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's... ► Artikel lesen | |
| 09.10.25 | IRLAB Therapeutics: IRLAB Appoints Gustaf Albèrt as the New Chief Financial Officer | 392 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / October 9, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 09.10.25 | IRLAB Therapeutics: IRLAB to Present at Redeye Theme: Neurology | 311 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 9, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments... ► Artikel lesen | |
| 02.10.25 | IRLAB Therapeutics: IRLAB Progresses Fully Funded IRL757 Study in Parkinson's Disease in Partnership with MSRD | 429 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / October 2, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg... ► Artikel lesen | |
| 04.09.25 | IRLAB Therapeutics: IRLAB Is Granted a Patent Strengthening the Market Exclusivity of The Drug Candidate Mesdopetam in China | 423 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / September 4, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced... ► Artikel lesen | |
| 29.08.25 | Change in Number of Shares and Votes in IRLAB Therapeutics AB | 424 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 29, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - During August 2025, the registered number of shares and votes in IRLAB Therapeutics AB ("IRLAB") has... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,420 | -0,79 % | Bayer: Das könnte zum Problem werden | Die Bayer-Aktie zeigt nach einer Erholung zuletzt wieder mehr Gegenwind im Chartbild. Im Fokus steht nun, ob sich die Erholung fortsetzen kann oder der Druck zunimmt Den vollständigen Artikel lesen... ► Artikel lesen | |
| NOVO NORDISK | 35,095 | +1,68 % | Novo Nordisk: Wegovy erhält EU-Zulassung für Lieferung ohne Kühlkette | Die Europäische Arzneimittelagentur EMA hat eine Aktualisierung der Produktinformation für Wegovy zugelassen, die es erlaubt, das Präparat bei der Auslieferung an Patienten bis zu 48 Stunden bei Temperaturen... ► Artikel lesen | |
| MERCK KGAA | 115,85 | -1,11 % | Eon will Heidelberg-Materials-Chef und Merck-Finanzchefin in den Aufsichtsrat holen | DJ Eon will Heidelberg-Materials-Chef und Merck-Finanzchefin in den Aufsichtsrat holen
DOW JONES--Der Netzbetreiber Eon will zwei hochrangige Manager in seinen Aufsichtsrat holen. Die Hauptversammlung... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,500 | -3,03 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| LB PHARMACEUTICALS | 29,115 | +9,58 % | Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating | ||
| OMNIAB | 1,480 | 0,00 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| PFIZER | 23,105 | +0,28 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 2,195 | +8,13 % | Milestone Pharmaceuticals initiiert Real-World-Studie für PSVT-Medikament CARDAMYST | ||
| ATRIUM THERAPEUTICS | 14,530 | +3,79 % | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 26,970 | -0,55 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| GRACE THERAPEUTICS | 4,360 | 0,00 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 | PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage... ► Artikel lesen | |
| NOVARTIS | 127,98 | -0,65 % | UBS stuft NOVARTIS AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novartis mit einem Kursziel von 116 Franken auf "Neutral" belassen. Mit seinen Schätzungen für Umsatz und operatives Ergebnis... ► Artikel lesen | |
| CANOPY GROWTH | 0,966 | -1,31 % | CANOPY GROWTH CORPORATION: Stabilität als Signal | ||
| GSK | 24,450 | -0,16 % | UBS stuft GSK auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für GSK mit einem Kursziel von 1940 Pence auf "Neutral" belassen. Analyst Matthew Weston geht mit moderat negativen Erwartungen... ► Artikel lesen | |
| ELI LILLY | 771,00 | +0,51 % | Novo Nordisk-Aktie: Kampfansage an Eli Lilly | Still ruht der See bei Novo Nordisk. Seit anderthalb Monaten klebt der Aktienkurs des dänischen Pharmakonzerns knapp über der 30 €-Marke. Kann diese Nachricht der Novo Nordisk-Aktie neuen Schwung verleihen... ► Artikel lesen |
Das Unternehmen IRLAB THERAPEUTICS AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,139 Euro und damit -1,28 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IRLAB THERAPEUTICS AB finden Sie auf Wallstreet Online.